Table 2.

Incidence, mortality, and disease forms of the control mice and curdlan-treated mice in experimental autoimmune encephalomyelitis (EAE) ^a .

Group b	Incidence c	Mortality d	Disease forms e
			Relapsing-remitting	Hyperacute	Secondary progressive
Control	10/12	2/10	8/10	1/10	1/10
Curdlan	11/12	9/11*	2/11	8/11	1/11

^aFor EAE induction, SJL/J mice were sensitized subcutaneously with the myelin proteolipid protein (PLP)_139-151 peptide emulsified in complete Freund’s adjuvant (CFA).

^bOne day prior to PLP_139-151 sensitization, mice from the control and curdlan treatment groups were injected intraperitoneally with phosphate-buffered saline (PBS) and curdlan, respectively.

^cNumber of symptomatic mice/total number of mice sensitized with the PLP_139-151/CFA emulsion.

^dNumber of dead mice/total number of symptomatic mice. *P < 0.05, χ² test, compared with controls.

^eNumber of mice with each disease form/total number of symptomatic mice.